Ambrose acquired AM-Pharma’s hypophosphatasia (HPP) candidate ilofotase alfa in a deal valuing the program at $181 million in milestones, with an undisclosed upfront payment. Ambrose said the asset’s Phase Ib work in adults with HPP supports a biomarker-driven, dose-dependent signal and a positive safety profile, while the transaction gives the rare-disease specialist a European operational base in Utrecht.